Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALNY

Alnylam Pharmaceuticals Inc

Dec 13 • 04:00PM ET

245.44

Dollar change +0.18
Percentage change 0.07	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO VXF VUG VOT IBB XBI IWP VHT IWR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.62	Insider Own	0.80%	Shs Outstand	128.84M	Perf Week	-4.22%
Market Cap	31.68B	Forward P/E	-	EPS next Y	-1.08	Insider Trans	-12.70%	Shs Float	127.94M	Perf Month	-7.24%
Income	-332.26M	PEG	-	EPS next Q	-0.56	Inst Own	96.57%	Short Float	2.65%	Perf Quarter	-9.22%
Sales	2.09B	P/S	15.12	EPS this Y	43.24%	Inst Trans	3.12%	Short Ratio	4.44	Perf Half Y	53.03%
Book/sh	0.25	P/B	977.38	EPS next Y	45.90%	ROA	-8.26%	Short Interest	3.39M	Perf Year	35.96%
Cash/sh	21.54	P/C	11.39	EPS next 5Y	-	ROE	-	52W Range	141.98 - 304.39	Perf YTD	28.23%
Dividend Est.	-	P/FCF	1972.62	EPS past 5Y	14.18%	ROI	-12.65%	52W High	-19.37%	Beta	0.32
Dividend TTM	-	Quick Ratio	2.69	Sales past 5Y	97.61%	Gross Margin	85.37%	52W Low	72.88%	ATR (14)	7.65
Dividend Ex-Date	-	Current Ratio	2.75	EPS Y/Y TTM	36.38%	Oper. Margin	-8.98%	RSI (14)	38.75	Volatility	3.04% 3.08%
Employees	2100	Debt/Eq	84.27	Sales Y/Y TTM	21.54%	Profit Margin	-15.86%	Recom	1.85	Target Price	305.46
Option/Short	Yes / Yes	LT Debt/Eq	80.17	EPS Q/Q	-175.33%	Payout	-	Rel Volume	0.68	Prev Close	245.26
Sales Surprise	-6.00%	EPS Surprise	5.08%	Sales Q/Q	-33.26%	Earnings	Oct 31 BMO	Avg Volume	764.64K	Price	245.44
SMA20	-1.35%	SMA50	-8.17%	SMA200	12.13%	Trades		Volume	516,784	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178
Mar-01-22	Initiated	Citigroup	Buy	$223
Feb-03-22	Upgrade	Guggenheim	Neutral → Buy	$170

Show Previous Ratings

Dec-04-24 12:00PM	What Makes Alnylam (ALNY) a New Buy Stock (Zacks)
Dec-02-24 02:48PM	Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-27-24 07:00AM	Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference (Business Wire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Nov-22-24 02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-18-24 07:24AM	Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment (Clinical Trials Arena)
Nov-17-24 09:30AM	Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose (Business Wire)
Nov-15-24 07:19PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -8.67%
Nov-06-24 12:26PM	Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Nov-04-24 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-01-24 10:34AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
03:05AM	Alnylam Pharmaceuticals Inc (ALNY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
01:11AM	Loading…
01:11AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
12:25AM	Q3 2024 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-31-24 10:00AM	Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks) -5.29%
09:10AM	Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:07AM	Alnylam: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
Oct-30-24 11:31AM	Cognizant signs deal to enhance Alnylams IT infrastructure (Verdict)
08:00AM	Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 (Business Wire)
Oct-28-24 09:16AM	Seeking Clues to Alnylam (ALNY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Oct-24-24 10:01AM	Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-24 12:00PM	Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-17-24 09:40AM	Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? (Zacks)
08:00AM	Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results (Business Wire)
Oct-16-24 08:00AM	Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Oct-09-24 12:14PM	Biotech Eyes Early Entry As Several Factors Could Unleash Shares (Investor's Business Daily)
07:00AM	Loading…
07:00AM	Protein prediction wins chemistry Nobel; Alnylam submits an all-important drug application (BioPharma Dive)
07:00AM	Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy (Business Wire)
Oct-08-24 07:41AM	Startup led by John Maraganore raises $135M to build future of RNAi (BioPharma Dive)
Oct-07-24 03:00AM	Judo Bio debuts with $100M and a plan to take RNA drugs to the kidney (BioPharma Dive)
Oct-01-24 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:03AM	Not Holding Alnylam Pharmaceuticals (ALNY) Hurt Fidelity Growth Strategies Funds Performance (Insider Monkey)
Sep-29-24 09:00AM	Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 (Business Wire)
Sep-26-24 08:00AM	Alnylam to Webcast TTR Investor Day (Business Wire)
Sep-14-24 07:03PM	Alnylam Pharmaceuticals, Inc. (ALNY): Hedge Funds Are Bullish on This Aggressive Growth Stock (Insider Monkey)
Sep-13-24 07:10PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Sep-12-24 01:01PM	The Brawl Taking Shape Over Pfizers Multibillion-Dollar Heart Monopoly (The Wall Street Journal)
Sep-08-24 02:01AM	Alnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now? (Insider Monkey)
Sep-06-24 07:09PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-30-24 04:19PM	Why IBD 50's Alnylam Just Reversed Its 50% Gain And BridgeBio Surged (Investor's Business Daily) -8.47%
04:03PM	Alnylam Stock Falls on Positive but Disappointing Study Results for Heart Drug (The Wall Street Journal)
02:33PM	ESC Congress: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
02:33PM	ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for Alnylam (Pharmaceutical Technology)
10:13AM	Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations (Investor's Business Daily)
06:00AM	Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran? in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress (Business Wire)
02:00AM	Full study data back Alnylam heart drugs benefit, but leave doctors with tough choices (BioPharma Dive)
Aug-28-24 04:00PM	Alnylam to Webcast Presentations at Upcoming September Investor Conferences (Business Wire)
Aug-23-24 10:22AM	Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition (Zacks)
Aug-21-24 02:45AM	Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q2 (Insider Monkey)
Aug-07-24 09:00AM	The 3 Best Gene Editing Stocks to Buy in August 2024 (InvestorPlace)
08:00AM	Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 (Business Wire)
Aug-04-24 06:55PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
Aug-02-24 09:45AM	Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues (Zacks)
06:39AM	Vir retreats from infectious disease; Vertex shelves AATD drugs (BioPharma Dive)
01:03AM	Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight (GuruFocus.com)
Aug-01-24 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +13.12%
11:30AM	Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:14AM	Alnylam: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity (Business Wire)
Jul-30-24 09:15AM	Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Jul-25-24 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jul-18-24 08:00AM	Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results (Business Wire)
06:05AM	Alnylam Stock Is a Blockbuster Biopharma In the Making (InvestorPlace)
Jul-11-24 06:30AM	35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success. (InvestorPlace)
Jul-09-24 06:00AM	7 Cheap Biotech Stocks With Major Upside Potential (InvestorPlace)
Jul-08-24 04:52AM	Pipeline Moves: Alnylams Amvuttra approval prospects up after Phase III win (Clinical Trials Arena)
Jul-05-24 03:01PM	Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings (GuruFocus.com)
Jun-25-24 07:45PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.74%
08:59AM	Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals (Zacks)
Jun-24-24 09:41PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +34.52%
04:11PM	Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug (Investor's Business Daily)
01:54PM	Alnylam Soars on Positive Heart-Drug Data (The Wall Street Journal)
01:54PM	Successful heart drug trial prompts Alnylam stock to jump 35 percent (Quartz)
01:05PM	US Treasury Secretary Janet Yellen speaks to Yahoo Finance (Yahoo Finance Video)
12:52PM	RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024 (Associated Press Finance)
12:42PM	Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran (Pharmaceutical Technology)
12:32PM	Tech sector growth, EU considers fining Apple: Morning Brief (Yahoo Finance Video)
10:53AM	Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug (Barrons.com)
10:52AM	Coffee Recall 2024: Over 250 Coffee Products Recalled Due to Botulism Fears (InvestorPlace)
10:33AM	Alnylam (ALNY) Stock Soars 30% on Heart Disease Drug Success (InvestorPlace)
10:25AM	Alnylam Stock Soars on Strong Results in Heart Drug Study (Investopedia)
10:24AM	Alnylam stock skyrockets on positive heart drug results (Yahoo Finance Video)
10:06AM	Alnylam Soars After Drug Meets Goal in Heart Disease Trial (Bloomberg)
08:51AM	Alnylam Stock Soars After Positive Results From Heart Disease Study (Barrons.com)
07:00AM	Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations (Business Wire)
06:49AM	Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock? (Zacks)
04:20AM	Alnylam says heart drug succeeds in closely watched study (BioPharma Dive)
04:20AM	Alnylam claims success in closely watched heart drug study (BioPharma Dive)
Jun-05-24 06:14AM	June's Biotech Boom: 3 Stocks to Buy for a Summertime Surge (InvestorPlace)
May-07-24 09:12AM	HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating (MT Newswires)
08:00AM	Alnylam Issues 2023 Corporate Responsibility Report (Business Wire)
May-03-24 01:01PM	Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:29PM	Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y (Zacks)
10:48AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
03:11AM	Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ... (GuruFocus.com)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garg Pushkal	CMO & EVP Dev & Med Affairs	Dec 12 '24	Sale	251.00	1,752	439,760	15,705	Dec 13 04:13 PM
Garg Pushkal	Officer	Dec 12 '24	Proposed Sale	255.02	1,752	446,795		Dec 12 04:05 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '24	Sale	250.98	5,219	1,309,853	78,880	Nov 27 05:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Nov 26 '24	Sale	250.98	1,682	422,144	17,457	Nov 27 05:22 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Nov 26 '24	Sale	250.98	1,682	422,144	30,644	Nov 27 05:21 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Nov 26 '24	Sale	250.98	1,469	368,686	13,191	Nov 27 05:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 27 '24	Sale	252.29	1,531	386,261	12,881	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 26 '24	Sale	250.98	1,469	368,686	14,412	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	Officer	Nov 27 '24	Proposed Sale	253.98	1,531	388,843		Nov 27 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Option Exercise	85.00	15,000	1,275,000	88,441	Aug 22 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Sale	280.00	15,000	4,200,000	73,441	Aug 22 08:01 PM
Greenstreet Yvonne	Officer	Aug 20 '24	Proposed Sale	280.00	15,000	4,200,000		Aug 20 05:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Option Exercise	89.09	20,725	1,846,429	34,906	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Sale	270.99	22,025	5,968,516	12,881	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	Officer	Aug 12 '24	Proposed Sale	269.52	22,025	5,936,178		Aug 12 04:07 PM
Ausiello Dennis A	Director	Aug 06 '24	Option Exercise	119.68	20,250	2,423,452	20,386	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Sale	262.00	20,250	5,305,586	136	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Proposed Sale	266.66	20,250	5,399,865		Aug 06 04:07 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Option Exercise	85.00	15,148	1,287,580	88,589	Aug 02 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Sale	270.00	15,148	4,089,960	73,441	Aug 02 08:01 PM
Greenstreet Yvonne	Officer	Aug 01 '24	Proposed Sale	270.00	15,148	4,089,960		Aug 01 04:01 PM
Greenstreet Yvonne	Chief Executive Officer	Jul 11 '24	Sale	261.00	7,093	1,851,273	73,441	Jul 12 08:02 PM
SCHULMAN AMY W	Director	Jun 25 '24	Option Exercise	131.21	8,500	1,115,285	16,936	Jun 27 04:04 PM
SCHULMAN AMY W	Director	Jun 25 '24	Sale	240.00	8,500	2,040,000	8,436	Jun 27 04:04 PM
PYOTT DAVID E I	Director	Jun 24 '24	Option Exercise	80.76	32,450	2,620,611	32,586	Jun 26 04:28 PM
PYOTT DAVID E I	Director	Jun 24 '24	Sale	220.69	32,450	7,161,360	136	Jun 26 04:28 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jun 25 '24	Sale	230.99	2,103	485,773	15,609	Jun 26 04:28 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 25 '24	Sale	230.99	8,301	1,917,475	80,534	Jun 26 04:27 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	28,892	Jun 26 04:26 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	11,660	Jun 26 04:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jun 25 '24	Sale	230.99	1,198	276,731	14,181	Jun 26 04:26 PM
SCHULMAN AMY W	Director	May 29 '24	Option Exercise	66.83	30,000	2,004,900	30,136	May 31 07:00 PM
SCHULMAN AMY W	Director	May 29 '24	Sale	148.60	21,700	3,224,546	8,436	May 31 07:00 PM
SHARP PHILLIP A	Director	Feb 29 '24	Option Exercise	59.25	30,000	1,777,500	30,000	Mar 01 04:12 PM
SHARP PHILLIP A	Director	Feb 29 '24	Sale	151.34	30,000	4,540,071	0	Mar 01 04:12 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '24	Option Exercise	0.00	1,667	0	5,737	Feb 29 04:18 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '24	Sale	155.30	501	77,805	5,236	Feb 29 04:18 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '24	Option Exercise	0.00	1,908	0	20,052	Feb 29 04:18 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '24	Sale	155.30	574	89,145	19,478	Feb 29 04:18 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '24	Option Exercise	0.00	5,921	0	51,060	Feb 29 04:18 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '24	Sale	155.31	2,932	455,357	48,128	Feb 29 04:18 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '24	Option Exercise	0.00	1,908	0	9,240	Feb 29 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '24	Sale	155.30	574	89,145	8,666	Feb 29 04:17 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 27 '24	Option Exercise	0.00	878	0	4,462	Feb 29 04:16 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 28 '24	Sale	155.30	329	51,094	4,133	Feb 29 04:16 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 16 '24	Sale	148.06	1,308	193,666	7,332	Feb 20 04:09 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 16 '24	Sale	148.06	1,007	149,099	18,144	Feb 20 04:08 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 16 '24	Sale	148.06	1,009	149,397	4,070	Feb 20 04:08 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 16 '24	Sale	148.06	7,030	1,040,885	45,139	Feb 20 04:07 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 01 '24	Option Exercise	0.00	5,175	0	5,175	Feb 05 04:05 PM
Franchini Indrani Lall	EVP, CLO & Secretary	Feb 02 '24	Sale	170.99	1,591	272,050	3,584	Feb 05 04:05 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Option Exercise	96.45	30,000	2,893,500	46,029	Dec 29 04:03 PM
BONNEY MICHAEL W	Director	Dec 27 '23	Sale	195.00	30,000	5,850,000	16,029	Dec 29 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALNY

Alnylam Pharmaceuticals Inc

Upgrade your FINVIZ experience